{"id":203194,"name":"EMERGENT BIOSOLUTIONS","slug":"emergent-biosolutions","state":"MD","country":"United States of America","description":"Global Life Science Company","totalSpending":360000,"filings":13,"yearlySpending":[{"year":2019,"income":120000},{"year":2020,"income":120000},{"year":2021,"income":120000}],"issues":["DIS","BUD","HOM","DEF","HCR","ALC"],"firms":["DOTCHIN & ASSOCIATES, LLC"],"lobbyists":["ROBERT DOTCHIN"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government \nRe-authorization of the Pandemic and All-Hazards Preparedne","FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government \nRe-authorization of the Pandemic and All-Hazards Preparedne","FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government \nRe-authorization of the Pandemic and All-Hazards Preparedne","FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government \nRe-authorization of the Pandemic and All-Hazards Preparedne","FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government\nRe-authorization of the Pandemic and All-Hazards Preparednes"],"years":[2019,2020,2021]}